The first scalable 3D culture product tailor made for pharmaceutical drug development.
We’ve built the first scalable 3D culture product tailor made for pharmaceutical drug development. Our testing plates feature 384 wells for high-throughput screening (HTS), containing 1 mini spheroid (~200 cells) per well to reduce cell cost/spheroid and eliminate imaging and necrosis issues. We implement a 2-step quality assurance to know that each spheroid is viable & the right shape. The product is cryopreserved to eliminate hassle of culturing models and compatible with existing lab equipment and workflows, making it an automation-compatible 3D platform.
Our Assay-ready 3D models are pre-seeded with qualified 3D spheroids/organoids with low contamination risk and full readiness for compound dispensing, washing, fixing, staining, and imaging. Just thaw and use.
Lucero’s first scalable 3D culture product, tailor-made for pharmaceutical drug development. Our testing plates feature 384 wells for high-throughput screening (HTS) containing single 200 cells (PHH or HepG2) liver mini spheroids in each well. This model reduces cell costs per spheroid while addressing imaging and necrosis concerns.
Our 3D spheroids/organoids undergo a 2-step quality assurance process, ensuring viability, size, and shape. Lucero’s assay-ready 3D models are cryopreserved to eliminate hassle of culturing models and compatible with existing lab equipment and workflows, delivering an automation-compatible 3D platform.
Lucero is built to lead Our assay-ready plates beat the competition in scale, quality, speed, and usability.
Founded in March 2020 in the Nordic life-science hub of Gothenburg, Sweden, LuceroBio is a bioconvergence company built on deep research in microbiology, Al, and microfluidics. We combine these technologies to create solutions that can help speed up the discovery of the next generation of personalized drugs and treatments.
LuceroBio was started in response to the growing need for better 3D cell culture tools in early-stage pharmaceutical drug discovery. Our current focus is on developing assay-ready 3D cell culture plates-a product designed to make it easier for researchers and pharmaceutical companies to use complex 3D models in their workflows. These plates come preloaded with cryopreserved human liver spheroids and are ready to use straight out of the freezer, removing the hassle of spheroid formation, culturing, and assay preparation.
We believe that 3D cell cultures are key to understanding how drugs behave in the human body. But for them to make a real impact, they need to be easy to use, consistent, and scalable. That’s what we aim to deliver with our platform-helping companies make better decisions, faster, and bring promising treatments to patients sooner.
Awards
